Is there a risk of esketamine misuse in clinical practice?
Therapeutic advances in drug safety 2025 Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al. 11 citations
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...